跳至主要内容
临床试验/NCT00212342
NCT00212342已完成3 期

Phase 3,Placebo Controlled,Randomized,Double-Blinded,NSAID-Add-on,Clinical Trial of Mono-phase Low Dose Oral Contraceptive Pill for Treatment of Dysmenorrhea Associated With Endometriosis.

Nobelpharma0 个研究点目标入组 100 人开始时间: 2004年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
100
主要终点
patient response to treatment for dysmenorrhea associated with endometriosis,as evaluated by VRS

研究概览

简要总结

The purpose of this study is to determine whether combination oral contraceptive pill of Norethindrone & Ethinyl estradiol is effective in the treatment of dysmenorrhea associated with endometriosis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • dysmenorrhea associated with endometriosis

排除标准

  • severe hepatopathy
  • pregnant woman

研究组 & 干预措施

Norethisterone,Ethinylestradiol

Experimental

干预措施: Norethisterone,Ethinylestradiol (Drug)

Sugar pill

Placebo Comparator

干预措施: Sugar pill (Drug)

结局指标

主要结局

patient response to treatment for dysmenorrhea associated with endometriosis,as evaluated by VRS

次要结局

  • changes in the VAS of dysmenorrhea.
  • changes in the VRS of non-menstrual pain.
  • changes in the VAS of non-menstrual pain.
  • changes in the clinical evaluation of pelvic induration.
  • changes in the size of ovarian endometrioma.

研究者

发起方
Nobelpharma
申办方类型
Industry

相似试验